Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma - Wikidata - wikimedia - TriplyDB

Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma

Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma

http://www.wikidata.org/entity/Q35613148

about

Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors CAR models: next-generation CAR modifications for enhanced T-cell function Chimeric antigen receptor T-cell therapy for solid tumors Synthetic biology approaches to engineer T cells Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy.Driving CAR T-cells forward A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells.Enhancing adoptive T cell immunotherapy with microRNA therapeutics.Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy.Cancer Immunotherapy: Whence and Whither.Optimizing T-cell receptor gene therapy for hematologic malignancies.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.The Principles of Engineering Immune Cells to Treat Cancer.Development of CAR T cells designed to improve antitumor efficacy and safety.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Adoptive T cell therapy: An overview of obstacles and opportunities.A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML.Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.Chimeric antigen receptor transduced T cells: Tuning up for the next generation.Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.Engineering chimeric antigen receptor-T cells for cancer treatment.PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.

P2860

Q26741260-363EA5FA-D6CB-4FA5-81C9-D923761E6165 Q26745600-7EA67B49-7E7A-4DE2-BBD1-51ECC524654B Q26750908-60533B8D-EE90-46A0-9FA9-F90F838F35D8 Q26798366-51E14E6C-92BA-4073-A60D-64638431B97F Q28068378-11A4097D-7DCF-454B-941B-01891D83958E Q28073563-39037ACB-FE8F-4FC8-9447-65A33A7250EB Q28073874-4E9378C4-0917-46C5-B12E-32C887B9A265 Q33664499-5708243F-DD89-455C-8E64-5BF1C727D473 Q34046505-393E20A6-F20A-4960-B534-FD131E9ADDA7 Q35627284-3B3CA9BE-6E9D-415E-9BBE-3C682E4F95EC Q36281621-D0459356-C43E-42CA-804D-E2E7DF1F63CD Q36821069-CE83D7D4-336D-473F-AF09-72D5B1CB2C1C Q36821236-386BFC0A-D9BE-40F8-BEBE-A12E024D1637 Q36889204-E07EF5ED-44A7-4B90-990A-14CD841A46EA Q36928580-173A686C-94F9-4A5D-A83C-C26805412A8E Q37058110-4F1F8A3F-BC58-4CA1-BD1B-47087D2678F6 Q37706331-9C4B38F0-7EF8-49EC-8FB1-094DAE477663 Q38703318-66441968-E5DD-460E-A02F-FCD569A61229 Q38730553-01915E7A-B2D2-42FC-A683-FEAE3FF28730 Q38737924-2C7123F4-C0E9-4ABC-A393-A3AA9BF6BB4D Q38840466-6F8CAF0E-01B3-4891-9D20-D2D6C206CF93 Q38873974-B893752E-453F-405C-A24B-065C89CE01E6 Q38874911-F831C50B-7CF4-42D0-BF7F-7021DA356B00 Q39130457-562FC792-D417-46F4-87D3-8AA45DFF1C05 Q39200527-9362B9E9-121B-4283-A8BA-6533D666B2CF Q39246685-6019DC36-6AA5-4C53-9C5C-A8CA885BA5D2 Q39256918-B389A72F-7046-4074-8D03-58DC03744248 Q39329596-DDFA4BFA-F53D-4E9C-9719-F60415B91937 Q41203830-2104172E-3B01-43F0-A820-B41E8156B131 Q41619752-6B2E15C1-F6B2-4293-A904-B67772D08328 Q41909592-56010621-4E22-4368-ABEE-6219C1334309 Q42576424-3126C074-3B23-49A2-B8C1-A74C702D141F Q45868285-8383D614-501F-421C-BA06-ABDB75D721A7 Q45871070-5F8C2AF3-9E50-424A-A3BE-ABA3D6A1FF1F Q47163146-EF8835EC-B451-4586-B1FE-B542F4A4660B Q48106124-55484248-6769-4466-BA50-EB88FA30BEEE Q48337005-0DA40582-7498-4AC8-A0DF-88019E5CA554 Q48648729-BC60A89B-3D7D-4A03-9F8C-E1D1E2CD84C7 Q49962991-9D4A97A4-C030-4F9A-98E7-B37F02D72FB0 Q54978680-73A6340C-8808-46DB-AC96-3F587F95EA35

P2860

Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma

http://www.wikidata.org/entity/Q35613148

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@ast

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@en

type

label

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@ast

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@en

prefLabel

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@ast

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@en

P1433

Q35613148-CDC91276-162C-4CED-A035-C35C5869B864

P1476

Q35613148-4161C3D5-2AC4-420A-8D49-308394E00FB5

P2093

Q35613148-0214F2D6-6359-4674-BF14-BDA61110B2DD

Q35613148-10893356-85BF-4B3B-ACF4-C582FBF27FFD

Q35613148-1210F3B6-8F8E-4A9D-A2C0-EFE510D01B34

Q35613148-2419F6EF-06D3-4160-9A5A-BA176AF5D8D6

Q35613148-28500216-5BBB-4D59-A5EA-B31F058A0E95

Q35613148-492BEAC4-ED92-493F-8C80-129B54606C2A

Q35613148-5ED4DAC7-468B-4680-A7EB-9BF124AFAB6C

Q35613148-7A912495-0DD5-4F6E-9563-CCD667B1D0B8

Q35613148-7D519C7F-CED3-400F-B4A6-BAD8C7420122

Q35613148-8DC2B3AE-6A33-4A64-8EBC-D9E3B0CA1E64

P2860

Q35613148-0144B444-48D3-4423-8CA6-01E2614E2276

Q35613148-22593038-4DE1-4EAC-B055-FA2B2BFCFC80

Q35613148-2B9F576D-43EB-41D7-B3D4-1EA1E3F9459B

Q35613148-2C77C4FA-45EC-4134-B4B2-44C0488C61A7

Q35613148-361144F4-9250-4B27-ADB2-43031E8E9898

Q35613148-36EB11DF-8E61-42D5-8D20-35E5D0B48DCB

Q35613148-4AC96708-DCD3-4E00-9212-3D830ACFC6D4

Q35613148-4F338853-1C39-4BB4-86DA-AEB68DD9F935

Q35613148-515612DC-F201-43ED-A4AE-4319A34FC470

Q35613148-6F5996AF-417C-463D-BC89-C34A204B9B2C

P304

Q35613148-C7276F2B-263A-49D9-8609-633D919DB766

P31

Q35613148-3F680391-0E32-4A27-87B5-E68599079F1E

P356

Q35613148-F4B3D81A-19C2-4A3D-9750-840E35BB5542

P407

Q35613148-63D926B7-79AB-4CC1-AB61-B2850B4E163D

P433

Q35613148-19F082BC-39A8-4896-A854-DF29F8DAADDD

P478

Q35613148-F27D3F97-1D2B-4004-BFA6-B82695790E0F

P50

Q35613148-E75BEB2A-E122-4FDF-A9E1-98D225F2077A

Q35613148-F9DB8251-D540-4CD6-8717-07525EEBE6D6

P577

Q35613148-72B80B04-67AB-4C3B-B152-519ABEC85195

P5875

Q35613148-6C9674F9-71B5-444E-B60A-CE0C9B7B8D14

P698

Q35613148-5D57D42C-372E-4C67-B635-E30F4770EBB8

P921

Q35613148-2A957B38-41F3-4EBE-88C1-15203A17BF16

P932

Q35613148-7ACDB2F7-CCD5-4FB2-A142-7FC9E7D23FF4

P356

1078-0432.CCR-14-2085

P1433

Clinical Cancer Research

P1476

Tumor-infiltrating lymphocytes ...... therapy of metastatic melanoma

@en

P2093

Azam V Nahvi

http://www.w3.org/2001/XMLSchema#string

Giao Q Phan

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Lien T Ngo

http://www.w3.org/2001/XMLSchema#string

Ling Zhang

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Mary Ann Toomey

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Richard M Sherry

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

IL-12 family cytokines: immunological playmakers

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

P304

2278-2288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-2085

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2015-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272517247

http://www.w3.org/2001/XMLSchema#string

P698

25695689

http://www.w3.org/2001/XMLSchema#string

P921

P932

4433819

http://www.w3.org/2001/XMLSchema#string